ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0700

Prospective Evaluation of Capillaroscopy in Healthy Children
Abstract Number: 0701

Diagnostic Performances of Vascular Biomarkers Soluble Fms-like Tyrosine Kinase (sFlt-1) and Placental Growth Factor (PlGF) in Scleroderma Renal Crisis: A Case Control Study
Abstract Number: 0702

AISA 021, a Novel Calcium Channel Antagonist in Development for Raynaud’s & Systemic Sclerosis, Has Antagonistic Activity at Sodium Channel Targets for Pain Relief and Treats Scleroderma Pain Better Than Current Calcium Channel Blockers in a Phase 2A Study
Abstract Number: 0703

Preliminary Results from the RECONNOITER Trial, a Phase 2 Study of AISA 021 in the Treatment of Secondary Raynaud’s, Primarily Due to Systemic Sclerosis
Abstract Number: 0704

Progression of Global Longitudinal Strain and Identification of Left Ventricular Dysfunction in Systemic Sclerosis Patients
Abstract Number: 0705

Identification of Risk Factors for Incident Cardiomyopathy in Patients with Systemic Sclerosis
Abstract Number: 0706

Single Center Prospective Cohort of Systemic Sclerosis Patients Who Are At-Risk for Pulmonary Hypertension
Abstract Number: 0707

Comprehensive Skin Assessment in Systemic Sclerosis Using Spatial Frequency Domain Imaging (SFDI)
Abstract Number: 0708

Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis
Abstract Number: 0709

Linear Combination of Principal Components Achieves Top Performance in Identifying Rheumatologist-Diagnosed Systemic Sclerosis from Electronic Health Records
Abstract Number: 0710

High S100A4 Levels Associate with Inflammation and Vasculopathy in Systemic Sclerosis
Abstract Number: 0711

Molecular Signatures in the Skin as Predictors of Longitudinal Clinical Trajectories in Patients with Systemic Sclerosis
Abstract Number: 0712

Efficacy of Sacubitril/Valsartan in Patients with Systemic Sclerosis and Heart Failure: A Retrospective Analysis
Abstract Number: 0713

Anti-muscarinic 3 Antibodies in SSc Associate with a More Significant GI and Extraintestinal Clinical Phenotype
Abstract Number: 0714

Therapeutic Dilemmas in Patients with ANCA-associated Vasculitis: Diffuse Alveolar Hemorrhage, Venous Thromboembolism and Anticoagulation

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].